• Explore /
  • Poster
  • / IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study.

IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study.

Abstract Video & Slides Poster

Authors

Nong Xu

Nong Xu

The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Nong Xu , Chenyu Mao , Jiong Qian , Yulong Zheng , Haiping Jiang , Yuan Gao , Cheng Xiao , Anwen Xiong , Wei Li , Yayi He , Shengxiang Ren , Lei Wang , Jia Yu , Jun Zhu , Ying Liu , Caicun Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)

Clinical Trial Registration Number

NCT04085185

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2650)

DOI

10.1200/JCO.2022.40.16_suppl.2650

Abstract #

2650

Poster Bd #

304

Abstract Disclosures

Similar Posters

First Author: Cai Zhou

First Author: Judy S. Wang

First Author: Russell J. Schilder

First Author: Dalia Kaakour